ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX. The poster being displayed, entitled "Vitamin B-12 Nanoparticles for the Targeted Delivery of RNAi Therapeutics", summarizes key findings of the Company's rebranded Cobalamin program, CobaCyte for RNAi. The second poster, entitled "Preclinical and Clinical Studies of ProLindac: A Novel Polymer Prodrug of DACH Platinum", details the distinct attributes and advantages of utilizing Access' second generation DACH Platinum, ProLindac.
"We are pleased to be included in this year's Innovations in Cancer Prevention and Research Conference as the team's research in both programs support a significant opportunity in treating various cancers," said David Nowotnik, Senior VP of Research and Development, Access Pharmaceuticals, Inc. He continued, "Given the recently commenced combination trial for ProLindac and the heightened interest surrounding our CobaCyte program, this conference, with its astute multidisciplinary audience, is an ideal venue to display the work currently under development at Access."
The conference is organized by the Cancer Prevention and Research Institute of Texas (CPRIT).
For information on the conference, please visit: http://cpritconference2010.eventbrite.com/
Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis